WuXi Bio signs deal to manufacture Viridian’s thyroid eye disease drugnews2026-05-27T13:55:31+00:00May 27th, 2026|Endpoints News|
#ASCO26: Cancer immunotherapy’s magic bullet era is fading. Here’s what’s nextnews2026-05-27T13:53:17+00:00May 27th, 2026|Endpoints News|
Signos raises $20M as it eyes health plan, pharma relationshipsnews2026-05-27T13:00:13+00:00May 27th, 2026|Endpoints News|
Waypoint Bio raises $20M to run three CAR-T trials in Chinanews2026-05-27T10:45:29+00:00May 27th, 2026|Endpoints News|
Kardigan readies Nasdaq IPO to back three cardio drugsnews2026-05-27T00:15:45+00:00May 27th, 2026|Endpoints News|
Post-Hoc Live: Jeremy Levin on biotech’s existential momentnews2026-05-26T17:39:25+00:00May 26th, 2026|Endpoints News|
Outlook says FDA will sign off on its version of Avastin for wet AMDnews2026-05-26T17:16:32+00:00May 26th, 2026|Endpoints News|
Cartesian secures funding to ‘accelerate’ launch; Editas sells $125M in stocknews2026-05-26T15:06:30+00:00May 26th, 2026|Endpoints News|
Can AI do scientific research? Billions chase hopes of superintelligencenews2026-05-26T15:00:33+00:00May 26th, 2026|Endpoints News|
